H Lundbeck A/S Investor Event Transcript
/-&
Okay. Hello, everybody. Welcome. Nice to see you all, and nice to you in our house this time. So welcome here, and thanks for taking your afternoon to be here today. I know your schedules are very busy, so we do appreciate the time you've taken to be here. And you've seen the forward-looking statement disclaimer, so we're not going to read the fine print. I'm hoping you've done that many times before.
This afternoon, I'm joined by a number of my esteemed colleagues from around our organization, and we'll be going through the current pipeline of Lundbeck. But we like -- we've kind of said, let's focus especially on the things that are most new to us and to you, and our organization at Lundbeck La Jolla Research Center and organization in Lundbeck Seattle biopharmaceuticals. So we'll spend a little bit more time on the -- those in the agenda and the R&D pipeline, but also a big focus on eptinezumab as it comes towards its PDUFA date.
So these are the folks that are joining me. They'll
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |